https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37191 Wed 30 Aug 2023 15:39:56 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45123 Wed 26 Oct 2022 16:14:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45004 P < .001). Most of this increase has come from procedures in New South Wales (441% increase). Australian PCI rate increased from 22 301 to 30 480. Rate of CABG decreased from 5418 to 5206. Conclusions: From 2007 to 2017, rates of RA trebled in Australia. This is despite stable rates of PCI and a fall in rates of CABG. There are several clinical explanations for this trend.]]> Wed 26 Oct 2022 09:49:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37279 p < 0.001)). Statistical analysis between groups was used to assess the outcomes of time to union, incidence of non-union, post-operative functionality, incidence of complications, progression to revision surgery, and mortality. A secondary multivariable analysis was used to assess risk factors for non-union and factors positively associated with union. Results: There were no significant differences in outcomes between groups. Union rates were 83.8% (57/68) in the periprosthetic group and 78.9% (45/57) in the non-periprosthetic group (p = 0.648). Comminution was identified as a significant risk factor for non-union (p = 0.005). Use of a submuscular technique had a significant positive association with union (p = 0.006). Conclusions: Outcomes of surgical treatment for periprosthetic and non-periprosthetic distal femur fractures are similar. There is a significant risk of non-union in locked plating of both groups.]]> Wed 16 Sep 2020 16:58:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34977 Tue 28 May 2019 13:23:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36672 65) and diagnosis (drug related and eating disorder). Conclusion: There is limited evidence around the patient profile and journey of people who present to EDs for mental health reasons, and this study contributes to this literature.]]> Tue 23 Jun 2020 12:57:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48575 P = 2/55; confidence interval = 0.44-12.53%). The cost comparison suggests the cost implementation of cCMV screening (and subsequent potential treatment benefits and management over time), compared to non-screening (and subsequent management), to be negligible. Conclusion: Incorporating cCMV testing into Universal Newborn Hearing Screening within Queensland is realistic and achievable, both practically and financially.]]> Tue 21 Mar 2023 16:55:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37694 Tue 16 Mar 2021 17:30:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36873 Tue 14 Jul 2020 10:23:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39502 n = 28) out of 1006 audited records, and only 10 (1%) of them were legally binding. The number of EGs appointed was 39 (3.9%) across the sites. A total of 151 (15.4%) resuscitation plans were found across the eight hospital sites. 95% (n = 144) of the resuscitation plans indicated ‘Not-for-resuscitation’. Conclusions: The uptake of ACP is very low. Current medical recording system reveals the challenges in ACP lie in the process of storage, access and execution of the ACDs. Given that having an ACD or Enduring Guardian in place is only useful if the treating physician knows how and where to access the information, it has implications for policy, information system, and healthcare professionals’ education. Trial registration: The study was retrospectively registered with the Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12618001627246). The URL of the trial registry record http://www.anzctr.org.au/trial/MyTrial.aspx]]> Tue 09 Aug 2022 14:39:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33779 Tue 03 Sep 2019 18:22:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33419 Tue 03 Sep 2019 18:01:44 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34967 Tue 03 Sep 2019 17:57:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35010 Thu 30 May 2019 14:51:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46820 Thu 01 Dec 2022 09:53:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38666 Mon 13 Dec 2021 15:52:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46867 Mon 05 Dec 2022 09:05:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35026 Salmonella (pooled OR = 4.84; 95% CI = 2.75-8.54; I²= 58.7%; P = 0.064) and Campylobacter (pooled OR = 5.09; 95% CI = 3-8.64; I²= 81%; P < 0.001) but lower for studies that combined all bacteria (pooled OR = 2.42; 95% CI = 0.96-6.14; I²= 94.3%; P < 0.001). Conclusion: PPI users have an increased risk of developing community-acquired enteric infections compared with nonusers. The heterogeneity was partially explained by type of microorganism; the association is stronger for Salmonella and Campylobacter than for all bacteria combined.]]> Fri 31 May 2019 16:52:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45488 Fri 28 Oct 2022 14:57:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53211 Fri 17 Nov 2023 11:55:31 AEDT ]]>